ENX-101

DRUG2 trials

Sponsors

Engrail Therapeutics Inc., Engrail Therapeutics INC

Conditions

Focal Epilepsyfocal (partial onset) epilepsy

Phase 2

ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

WithdrawnNCT05481905

Engrail Therapeutics INCFocal Epilepsy

Start: 2022-09-30End: 2024-12-31Updated: 2023-07-06

The ENACT Trial: A Randomized, double-blind, placebo-controlled adjunctive treatment trial to evaluate the efficacy and safety of ENX-101 in patients with focal (partial onset) seizures

Not yet recruitingCTIS2022-501028-95-00

Engrail Therapeutics Inc.focal (partial onset) epilepsy

Target: 72Updated: 2022-12-13